Clinical Studies May Be Needed For Cosmetics With Nanomaterials – FDA
This article was originally published in The Rose Sheet
Executive Summary
Due to nanomaterials’ size and the unique behavior they often exhibit, standard tests – and particularly in vitro tests – for assessing product safety may not be appropriate for use, FDA says in new guidance to the cosmetics industry. The agency encourages firms to consult with its cosmetics office prior to launching nanotech-containing products to market.